This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): MLN591DM1
Description: Like MLN591RL, MLN2704 consists of a targeting monoclonal antibody vehicle (T-MAV) designed to deliver a lethal payload specifically to tumor cells that express prostate-specific membrane antigen (PSMA) on their surfaces. In the case of MLN2704, the lethal payload consists of a the chemotherapeutic agent drug maytansinoid (DM1), which has been conjugated to the T-MAV. In preclinical studies, after binding to PSMA on the surface of a tumor cell, the T-MAV was transported inside the cell, which was then killed by the chemotherapeutic agent carried by the T-MAV. PSMA is expressed on virtually all prostate cancer cells, both primary and metastatic, and its abundance on the cell surface increases as the cancer progresses.
J591, the parent antibody of MLN2704, was developed by BZL Biologics, which partnered with Millennium in April 2001 to develop MLN591RL and other constructs that use the J591 antibody.
ImmunoGen developed the DM1 conjugate. Millennium licensed the DM1 technology from ImmunoGen in February 2002 to develop MLN2704.
In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The acquisition closed in May 2008.
Partners: BZL Biologics, LLC ImmunoGen, Inc.
Additional information available to subscribers only: